Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: A pooled analysis of six double-masked, randomized, active-controlled clinical trials

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 759-765

  Wirta, David ^a   van Denburgh, Amanda M ^b   Weng, Emily ^b   Whitcup, Scott M ^b   Kurstjens, Sef ^b   Beddingfield III, Frederick C ^b,c  

^a Private Practice   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Eyelids; Intraocular pressure; Medical treatment; Pharmacology

Indexed keywords

BIMATOPROST;

ADULT; AGED; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRY EYE; EYE IRRITATION; EYELASH; FEMALE; GLAUCOMA; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79958802188     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S17457     Document Type: Article

References (19)

1. Lumigan [package insert]. Irvine, CA: Allergan, Inc; 2006.
2. Cracknell KP, Grierson I. Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects. Exp Eye Res. 2009;88(4): 786-791.
3. Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008;7(6):801-808.
4. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36(3): 504-511.
5. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S347-S351.
6. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(Suppl 1):S45-S52.
7. Whitcup SM, Cantor LB, VanDenburgh AM, Chen K; For the Bimatoprost Study Group II. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol. 2003;87(1): 57-62.
8. Higginbotham EJ, Schuman JS, Goldberg I, et al; For the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimato-prost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120(10):1286-1293.
9. Williams RD, Cohen JS, Gross RL, Liu C-C, Safyan E, Batoosingh AL; For the Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for IOP lowering in glaucoma and ocular hypertension: Year 4. Br J Ophthalmol. 2008;92(10):1387-1392.
10. Woodward DF, Liang Y, Krauss AH-P. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. 2008;153(3): 410-419.
11. Latisse [package insert]. Irvine, CA: Allergan, Inc; 2009.
12. Smith S, Fagien S, Somogyi C, Whitcup SM, Beddingfeld FC. Eyelash growth in subjects treated with bimatoprost ophthalmic solution 0.03%; a multicenter, randomized, double-masked, vehicle-controlled, parallel study. Poster presented at the 67th annual meeting of the American Academy of Dermatology, March 6-9, 2009, San Francisco, CA.
13. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349-358.
14. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM; For the Bimatoprost Study Group 1. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology. 2001;108(6):1023-1031.
15. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I. Bimatoprost/timolol fixed combination: A 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3): 211-216.
16. Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL; For the Ganfort Investigators Group II. The safety and effcacy of bimatoprost/timolol fxed combination: A 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2009;19(6): 424-426.
17. Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149(4):66-71.
18. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45-52.
19. Chen J, Dinh T, Woodward DF, et al. Bimatoprost: Mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev. 2005;23(3):231-246.